These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15789121)

  • 1. How molecular profiling could revolutionize drug discovery.
    Stoughton RB; Friend SH
    Nat Rev Drug Discov; 2005 Apr; 4(4):345-50. PubMed ID: 15789121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
    Hu S; Yen Y; Ann D; Wong DT
    Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling approaches for identifying novel biomarkers.
    Bailey WJ; Ulrich R
    Expert Opin Drug Saf; 2004 Mar; 3(2):137-51. PubMed ID: 15006720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
    Phan JH; Quo CF; Wang MD
    Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of molecular diagnostics with therapeutics: implications for drug discovery and patient care.
    Ross JS; Ginsburg GS
    Expert Rev Mol Diagn; 2002 Nov; 2(6):531-41. PubMed ID: 12465450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.
    Ferrer-Alcón M; Arteta D; Guerrero MJ; Fernandez-Orth D; Simón L; Martinez A
    Toxicol Lett; 2009 Apr; 186(1):45-51. PubMed ID: 19022361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
    Fischer HP
    Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of toxicogenomics to drug development.
    Lakkis MM; DeCristofaro MF; Ahr HJ; Mansfield TA
    Expert Rev Mol Diagn; 2002 Jul; 2(4):337-45. PubMed ID: 12138498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
    Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
    Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicogenomics in drug discovery: from preclinical studies to clinical trials.
    Yang Y; Blomme EA; Waring JF
    Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
    Ganter B; Tugendreich S; Pearson CI; Ayanoglu E; Baumhueter S; Bostian KA; Brady L; Browne LJ; Calvin JT; Day GJ; Breckenridge N; Dunlea S; Eynon BP; Furness LM; Ferng J; Fielden MR; Fujimoto SY; Gong L; Hu C; Idury R; Judo MS; Kolaja KL; Lee MD; McSorley C; Minor JM; Nair RV; Natsoulis G; Nguyen P; Nicholson SM; Pham H; Roter AH; Sun D; Tan S; Thode S; Tolley AM; Vladimirova A; Yang J; Zhou Z; Jarnagin K
    J Biotechnol; 2005 Sep; 119(3):219-44. PubMed ID: 16005536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomics and proteomics in process development: opportunities and challenges.
    Gupta P; Lee KH
    Trends Biotechnol; 2007 Jul; 25(7):324-30. PubMed ID: 17475353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical biomarkers in drug discovery and development.
    Frank R; Hargreaves R
    Nat Rev Drug Discov; 2003 Jul; 2(7):566-80. PubMed ID: 12838269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular biomarkers in drug development.
    Lewin DA; Weiner MP
    Drug Discov Today; 2004 Nov; 9(22):976-83. PubMed ID: 15539141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural proteomics in drug discovery.
    Tari LW; Rosenberg M; Schryvers AB
    Expert Rev Proteomics; 2005 Aug; 2(4):511-9. PubMed ID: 16097885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrating genomics across drug discovery and development.
    Debouck C
    Toxicol Lett; 2009 Apr; 186(1):9-12. PubMed ID: 18930125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico prediction of clinical efficacy.
    Michelson S; Sehgal A; Friedrich C
    Curr Opin Biotechnol; 2006 Dec; 17(6):666-70. PubMed ID: 17046236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.